Display options
Share it on

Pharmaceutics. 2021 Jun 17;13(6). doi: 10.3390/pharmaceutics13060894.

Preclinical In Vitro Studies with 3D Spheroids to Evaluate Cu(DDC).

Pharmaceutics

Friederike Hartwig, Monika Köll-Weber, Regine Süss

Affiliations

  1. Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, University of Freiburg, Sonnenstr. 5, 79104 Freiburg, Germany.

PMID: 34204205 PMCID: PMC8234124 DOI: 10.3390/pharmaceutics13060894

Abstract

Preclinical in vitro studies of drug candidates for anticancer therapy are generally conducted on well-established 2D cell models. Unfortunately, these models are unable to mimic the properties of in vivo tumors. However, in vitro 3D models (spheroids) have been proven to be superior in reflecting the tumor microenvironment. Diethyldithiocarbamate (DDC

Keywords: 3D spheroids; Cu(DDC)2; Disulfiram; drug delivery; liposomes; neuroblastoma; storage stability

References

  1. J Biol Chem. 2001 Feb 16;276(7):4972-80 - PubMed
  2. Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12877-82 - PubMed
  3. Pharmacol Rev. 2016 Jul;68(3):701-87 - PubMed
  4. Eur J Pharm Biopharm. 2019 Jul;140:20-28 - PubMed
  5. ACS Omega. 2020 Aug 13;5(33):21162-21171 - PubMed
  6. Br J Cancer. 2012 Oct 23;107(9):1488-97 - PubMed
  7. Toxicol Res (Camb). 2015 Nov 19;4(6):1439-1442 - PubMed
  8. J Mater Chem B. 2014 Jul 7;2(25):4021-4033 - PubMed
  9. PLoS One. 2016 Apr 07;11(4):e0153416 - PubMed
  10. Drug Discov Today. 2013 Mar;18(5-6):240-9 - PubMed
  11. Nat Protoc. 2010 Feb;5(2):267-81 - PubMed
  12. ISRN Pharm. 2012;2012:636743 - PubMed
  13. J Mol Biol. 1965 Aug;13(1):238-52 - PubMed
  14. BMC Cancer. 2018 Jul 21;18(1):753 - PubMed
  15. Chem Phys Lipids. 1993 Sep;64(1-3):3-18 - PubMed
  16. Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20009-14 - PubMed
  17. BMC Cancer. 2016 Oct 10;16(1):781 - PubMed
  18. Int J Pharm. 2012 Jul 15;431(1-2):120-9 - PubMed
  19. Int J Nanomedicine. 2017 Aug 02;12:5511-5523 - PubMed
  20. Adv Pediatr. 2011;58(1):297-311 - PubMed
  21. Cancer Res. 2006 Nov 1;66(21):10425-33 - PubMed
  22. Assay Drug Dev Technol. 2014 May;12(4):207-18 - PubMed
  23. Eur J Pharm Sci. 2010 Nov 20;41(3-4):546-55 - PubMed
  24. Br J Cancer. 2013 Oct 1;109(7):1876-85 - PubMed
  25. Acta Psychiatr Scand Suppl. 1992;369:15-26 - PubMed
  26. Bull Cancer. 1998 Sep;85(9):785-93 - PubMed
  27. Nat Protoc. 2009;4(3):309-24 - PubMed
  28. Bioconjug Chem. 2019 May 15;30(5):1371-1384 - PubMed
  29. Int J Cancer. 2004 Nov 20;112(4):713-21 - PubMed
  30. Nat Rev Cancer. 2020 Mar;20(3):174-186 - PubMed
  31. Semin Pediatr Surg. 2012 Feb;21(1):2-14 - PubMed
  32. J Control Release. 2008 Jan 4;125(1):16-24 - PubMed
  33. Oncoscience. 2015 Feb 20;2(2):91-8 - PubMed
  34. Biochim Biophys Acta. 1979 Oct 19;557(1):9-23 - PubMed
  35. J Biol Chem. 1959 Mar;234(3):466-8 - PubMed
  36. J Phys Chem B. 2007 Feb 15;111(6):1393-401 - PubMed
  37. Hum Genet. 1991 Apr;86(6):562-6 - PubMed
  38. Biomed Pharmacother. 2019 Oct;118:109371 - PubMed
  39. Biotechnol Bioeng. 2019 Jan;116(1):206-226 - PubMed
  40. J Immunol Methods. 1983 May 27;60(1-2):115-24 - PubMed
  41. Int J Nanomedicine. 2017 May 31;12:4129-4146 - PubMed
  42. Int J Mol Sci. 2018 Jan 09;19(1): - PubMed
  43. Langmuir. 2007 May 22;23(11):6289-93 - PubMed
  44. N Engl J Med. 2010 Jun 10;362(23):2202-11 - PubMed
  45. Cell Death Differ. 2005 Nov;12(11):1390-7 - PubMed

Publication Types